JLE - European Journal of Dermatology - Psoriasis vulgaris in a hepatitis B virus carrier
successfully treated with secukinumab and entecavir combination therapy JLE Home Bookstore …

Background Ustekinumab, an interleukin (IL)‐12 and IL‐23 blocker, has emerged as a new
therapeutic option for patients with psoriasis. It is generally well tolerated but safety data on …

Background Obesity is a common comorbidity of psoriasis and can attenuate response to
biologic treatment. Objectives To investigate the efficacy, safety and tolerability of …

Biological drugs are pharmaceuticals manufactured using biotechnology methods that may
target specific cytokines, cytokine receptors or surface molecules, and modulate the …

Background Biologics targeting interleukin 17 are increasingly being used for treatment of
moderate-to-severe psoriasis, but data on drug survival for these therapies remain scarce …

Background Secukinumab has demonstrated high, sustained efficacy in psoriasis to 52
weeks on a fixed-interval regimen. Objective We sought to compare a retreatment-as …

Background Secukinumab is a fully human monoclonal antibody that selectively neutralizes
interleukin‐17A and shows long‐lasting efficacy and safety in plaque psoriasis. More …

Introduction In light of the current Covid-19 pandemic and the ongoing, extensive debate
about the use of biological agents in psoriatic patients, we felt compelled to relate our …

DEAR EDITOR, Loss of efficacy of biological therapies in patients with psoriasis is a well-
known event. Biological switching is common in clinical practice, especially in tumour …

Background Secukinumab, a fully human monoclonal antibody that selectively neutralizes
interleukin 17A, has demonstrated strong and sustained efficacy in adults with moderate to …